Acute respiratory failure: nursing assessment and interventions

Acute respiratory failure (ARF) is the inability of the respiratory system to maintain adequate gas exchange – oxygenation, ventilation, or both – to meet the body’s metabolic demands. It is defined by specific arterial blood gas criteria: a PaO2 below 60 mmHg (hypoxemia), a PaCO2 above 45 mmHg with accompanying hypoxemia (hypercapnia), or both. Without rapid recognition and intervention, ARF progresses to respiratory arrest and death. It is one of the most critical conditions a nurse will encounter, and it is a high-frequency NCLEX topic.

Understanding ARF requires mastery of two core concepts: the classification system (Type I vs Type II) and the physiological reasoning behind each intervention. This reference provides a comprehensive guide to both, covering causes, clinical presentation, ABG patterns, oxygen delivery, non-invasive ventilation, intubation criteria, medications, and NCLEX differentiation. Pair it with the ABG interpretation guide, the ARDS nursing reference, the mechanical ventilation nursing guide, and the COPD nursing reference – all four conditions overlap closely in critical care.

Defining acute respiratory failure

Acute respiratory failure occurs when the lungs cannot perform their fundamental functions: delivering oxygen to the blood and removing carbon dioxide. Clinically, ARF is defined by ABG criteria rather than symptoms alone:

• Hypoxemic ARF: PaO2 < 60 mmHg on room air (or PaO2/FiO2 ratio < 300 mmHg)
• Hypercapnic ARF: PaCO2 > 45 mmHg with accompanying hypoxemia and respiratory acidosis (pH < 7.35)
• Combined ARF: Both criteria present simultaneously – the most severe form

The onset distinguishes acute from chronic. Acute failure develops within minutes to hours; chronic failure (as in end-stage COPD) develops over months to years and may be partially compensated. Acute-on-chronic is the most complex presentation: a patient with chronically elevated PaCO2 who decompensates further, and whose “normal” baseline is already outside standard reference ranges. For nursing assessment, a baseline ABG – when available – is essential context.

The two-type classification is the framework the NCLEX uses to test ARF, and it maps directly to clinical decision-making: which oxygen delivery device, whether to use BiPAP, whether supplemental oxygen alone will help, and what medications to prepare.

Type I: hypoxemic respiratory failure

Mechanism

Type I ARF is fundamentally an oxygenation problem. The lungs fail to transfer oxygen from the alveoli into the pulmonary circulation efficiently. Three mechanisms drive this:

Ventilation-perfusion (V/Q) mismatch is the most common cause. In a normal lung, ventilation and perfusion are matched – alveoli receive both air and blood flow. When alveoli are ventilated but not perfused (V/Q > 1, dead space), or perfused but not ventilated (V/Q < 1, shunt), gas exchange is impaired. The shunt fraction is the proportion of cardiac output that bypasses ventilated alveoli and returns to the systemic circulation deoxygenated.

True shunt is the extreme end of V/Q mismatch: alveoli are completely collapsed or flooded and receive zero ventilation. The defining characteristic of shunt physiology is that supplemental oxygen does not correct hypoxemia – because no oxygen reaches the collapsed alveoli to enrich the blood flowing through them. This is the hallmark of ARDS and is why 100% FiO2 may still leave a patient hypoxic.

Diffusion impairment occurs when the alveolar-capillary membrane thickens (as in pulmonary fibrosis) or surface area is lost, slowing oxygen transfer. This is less commonly the primary mechanism in acute ARF but contributes in several conditions.

Causes of Type I ARF

Type II: hypercapnic respiratory failure

Mechanism

Type II ARF is a ventilation problem. The lungs move insufficient air to clear the carbon dioxide produced by metabolism. CO2 accumulates in the blood (hypercapnia: PaCO2 > 45 mmHg), and because CO2 dissolves in water to form carbonic acid, the result is respiratory acidosis (pH < 7.35).

The alveolar ventilation equation explains the relationship: PaCO2 is inversely proportional to alveolar ventilation. Cut ventilation in half; PaCO2 doubles. Hypoventilation – whether from obstructed airways, weakened respiratory muscles, blunted central drive, or chest wall restriction – is the shared mechanism across all Type II causes.

Hypoxemia in Type II failure develops secondary to hypoventilation: as CO2 rises and displaces oxygen in the alveoli (per the alveolar gas equation), PaO2 falls. The low oxygen is a downstream consequence of the ventilation failure.

Causes of Type II ARF

ABG interpretation in acute respiratory failure

The ABG interpretation guide provides the complete 5-step ROME method. This section focuses specifically on the ABG patterns characteristic of ARF and how to read them in clinical context.

Normal ABG values for reference:

• pH: 7.35–7.45
• PaCO2: 35–45 mmHg
• PaO2: 80–100 mmHg
• HCO3: 22–26 mEq/L
• SaO2: 95–100%

Critical clinical point: Interpret every PaCO2 against the patient’s own baseline. In a COPD patient whose usual PaCO2 is 55–60 mmHg, a value of 40 mmHg looks normal on the lab report but means they are hyperventilating well beyond their usual pattern, usually in response to an acute insult such as worsening hypoxemia, and the HCO3 retained from chronic compensation will push the pH alkalotic. That extra work cannot be sustained. A PaCO2 that then climbs back toward, and above, baseline is the fatigue signal.

Clinical presentation

Signs and symptoms

ARF typically presents with a cluster of respiratory, neurological, and cardiovascular findings. The pace of deterioration depends on the type and cause.

Respiratory findings – both types:

• Dyspnea – often severe; patient may be unable to complete sentences
• Tachypnea – respiratory rate typically > 25–30 breaths/min
• Accessory muscle use – sternocleidomastoid, scalene muscles visible during inspiration
• Intercostal and suprasternal retractions in severe cases
• Paradoxical breathing (abdominal and chest move in opposite directions) – a sign of impending respiratory arrest from diaphragmatic failure
• Cyanosis – central (lips, mucous membranes) indicates severe hypoxemia (SpO2 typically < 85%)

Additional findings in Type I hypoxemia:

• Agitation and anxiety – often the first behavioral sign of hypoxemia before SpO2 changes
• Bilateral crackles (pulmonary edema, ARDS, pneumonia)
• Diminished or absent breath sounds (pneumothorax, massive atelectasis)

Additional findings in Type II hypercapnia (CO2 narcosis):

• Confusion and drowsiness – CO2 accumulation depresses the CNS; a patient becoming sleepy during an exacerbation is deteriorating
• Asterixis – the flapping hand tremor produced by metabolic encephalopathy from CO2 retention; ask the patient to extend both arms and hold – a flapping movement with inability to maintain posture indicates CO2 narcosis
• Bounding pulse and warm flushed skin – CO2 causes peripheral vasodilation and increased cardiac output
• Headache – CO2 is a cerebral vasodilator; increased cerebral blood flow causes throbbing headache
• Diaphoresis – from increased work of breathing and sympathetic activation

Late / preterminal signs in any ARF:

• Bradypnea and decreasing respiratory effort – the patient stops fighting, respiratory rate falls
• Cyanosis, pallor, diaphoresis
• Bradycardia and hypotension
• Loss of consciousness

Nursing assessment priorities

Primary survey: airway, breathing, circulation

ARF is managed with the primary survey (ABC) framework first. No assessment detail matters until airway patency and breathing adequacy are confirmed.

Airway: Is the airway open and maintained? Listen for stridor (upper airway obstruction), gurgling (secretions), or absent breath sounds. A patient who cannot protect their airway (GCS ≤ 8, loss of gag reflex) requires immediate escalation – the airway is not safe.

Breathing: Rate, depth, rhythm, symmetry. Auscultate all lung fields. Absent breath sounds on one side? Suspect pneumothorax or massive effusion. Bilateral crackles? Pulmonary edema or ARDS. Wheezing? Bronchospasm (asthma, COPD, anaphylaxis). Count the respiratory rate – do not estimate. A rate > 30 is ominous. If the rate falls from 30 to 18 while the patient looks worse (drowsier, weaker effort), treat it as a warning of impending arrest; improvement shows up as a slower rate together with a calmer, more alert patient.

Circulation: Assess heart rate, blood pressure, capillary refill, skin color and temperature. Tachycardia in ARF is initially compensatory. Hypotension signals the need to consider septic shock, tension pneumothorax, massive PE, or cardiac dysfunction. Urine output ≥ 0.5 mL/kg/hr indicates adequate end-organ perfusion.

Monitoring

• Continuous SpO2 – essential but has limitations: pulse oximetry is inaccurate in poor perfusion, nail polish, motion artifact, and severe anemia (carboxyhemoglobin will read falsely normal in CO poisoning)
• ABG – gold standard for PaO2, PaCO2, pH, and HCO3. Obtain after initiating supplemental O2, after any ventilator change, and when clinical status changes
• End-tidal CO2 (EtCO2) – continuous non-invasive CO2 monitoring; normal EtCO2 is 35–45 mmHg. Rising EtCO2 in a spontaneously breathing patient indicates hypoventilation and CO2 retention
• Respiratory rate – counted manually for 60 seconds; one of the earliest and most sensitive warning signs of deterioration
• Mental status – confusion, agitation, drowsiness are all clinical indicators that must be reassessed continuously; any unexplained mental status change in a respiratory patient warrants ABG

Oxygen therapy and titration

Matching the oxygen delivery device to the clinical situation is a core nursing skill. The goal is to correct hypoxemia without causing harm – particularly in patients at risk for CO2 retention.

Oxygen-induced hypercapnia – why “hypoxic drive” is only part of the story

Nursing texts often explain the risk of high-flow oxygen in COPD with the “hypoxic drive” theory: chronically raised PaCO2 blunts the central chemoreceptors, so breathing comes to depend on the peripheral chemoreceptors (carotid and aortic bodies) sensing low PaO2, and removing the hypoxemia removes the stimulus to breathe. The risk is real, but the mechanism is more mixed than that. The British Thoracic Society (BTS) 2017 oxygen guideline lists at least six likely mechanisms, ranked in order of importance:

1. Worsened V/Q matching (the main factor). Poorly ventilated lung units are normally kept poorly perfused by hypoxic pulmonary vasoconstriction. High-concentration oxygen reverses that vasoconstriction and sends more blood through units that still cannot clear CO2, so PaCO2 rises.
2. Reduced ventilatory drive. Relieving hypoxemia does reduce ventilation, but BTS notes clinical studies suggesting this “hypoxic drive” effect makes only a small contribution, and it adds little once PaO2 is above about 100 mmHg (13 kPa).
3. The Haldane effect. Fully oxygenated hemoglobin carries less CO2, so more CO2 is released into the plasma.
4. Absorption atelectasis, which can occur at an FiO2 as low as 30–50% and adds shunt.
5. The higher density of oxygen relative to air, which slightly increases the work of breathing.
6. Rebreathing when a face mask is run at too low a flow.

The classic physiology study by Aubier and colleagues (1980) gave 100% oxygen to COPD patients in acute respiratory failure: minute ventilation fell by about 18% at first but recovered to 93% of baseline within 15 minutes, yet PaCO2 still rose by an average of 23 mmHg. The authors attributed the rise mainly to worsening V/Q distribution.

The practical rule is the same whichever mechanism dominates. For COPD and other patients at risk of hypercapnic respiratory failure, BTS recommends a target SpO2 of 88–92%, starting with a 24% Venturi mask at 2–3 L/min, a 28% Venturi mask at 4 L/min, or nasal cannula at 1–2 L/min, and rechecking blood gases after 30–60 minutes. If the blood gas shows a normal PaCO2, BTS advises adjusting the target to 94–98%, unless the patient has a history of hypercapnic respiratory failure that needed NIV or intubation. Austin and colleagues (2010) found that prehospital titrated oxygen in suspected COPD exacerbation reduced mortality by 58% overall, and by 78% in confirmed COPD, compared with high-flow oxygen.

Two safety points follow. Never withhold oxygen from a hypoxemic COPD patient; titrate it. And never stop oxygen abruptly in a patient who has become hypercapnic on too much of it: CO2 stores stay high, so PaO2 can fall below the level it was at before oxygen was started (rebound hypoxemia). Step down gradually while monitoring SpO2 continuously.

Non-invasive ventilation (NIV)

Non-invasive ventilation delivers positive pressure via a tight-fitting mask, avoiding the complications of intubation. For appropriate candidates, NIV reduces intubation rates, ICU length of stay, and mortality.

BiPAP for Type II ARF

BiPAP is the first-line intervention for COPD exacerbation with hypercapnic respiratory failure. The BTS/ICS 2016 guideline recommends starting NIV when a respiratory acidosis (pH < 7.35 with PaCO2 > 6.5 kPa, about 49 mmHg) persists or develops despite optimal medical therapy, including controlled oxygen at 88–92%. The evidence base is robust: in the 2017 Cochrane review (Osadnik and colleagues), NIV added to usual care reduced the risk of death by 46% and the need for intubation by 65% in acute hypercapnic COPD exacerbation, and shortened hospital stay. The ERS/ATS 2017 guideline makes a strong recommendation for bilevel NIV in this group.

BiPAP delivers two pressure levels:

• IPAP (inspiratory positive airway pressure): Assists each inhalation – reduces the work of breathing and augments tidal volume, improving CO2 clearance
• EPAP (expiratory positive airway pressure): Maintains airway patency during exhalation – splints open airways and prevents alveolar collapse; equivalent to PEEP. An EPAP of at least 3 cmH2O is needed to flush exhaled CO2 out of the mask

Initial settings: BTS/ICS 2016 suggests starting IPAP around 15 cmH2O and increasing it to 20–30 cmH2O within 10–30 minutes as tolerated, noting that national audits found IPAP is often set too low. EPAP is usually started low (commonly 4–5 cmH2O) and raised for persistent hypoxemia, upper airway obstruction, or obesity hypoventilation. Settings are then titrated to respiratory rate, tidal volume, comfort, and the ABG response.

BiPAP is also used in:

• Obesity hypoventilation syndrome
• Acute-on-chronic respiratory failure
• Cardiogenic pulmonary edema (when CPAP is unavailable or insufficient)

Contraindications to NIV

BiPAP/CPAP are contraindicated in situations where a tight mask seal cannot be maintained safely or where the patient cannot protect their airway:

• Inability to protect the airway – vomiting, massive hemoptysis, impaired cough and gag reflex; aspiration risk is high with positive pressure into an unprotected airway
• Altered mental status / agitation – a confused or combative patient will not tolerate or maintain a mask seal; risk of dislodging the mask mid-session
• Facial trauma or burns – mask cannot form a seal; lesions may worsen with pressure
• Hemodynamic instability – hypotension not responsive to fluids is a relative contraindication; positive pressure reduces venous return
• Recent upper GI surgery – risk of anastomotic leak or rupture with pressurized delivery
• Active vomiting – aspiration risk is acute and immediate

CPAP for Type I ARF

CPAP provides a single continuous pressure throughout the respiratory cycle. It recruits collapsed alveoli and reduces the work of breathing but does NOT augment tidal volume. It is appropriate for Type I ARF patients who:

• Have an intact respiratory drive and can breathe spontaneously
• Are not primarily retaining CO2 (CPAP keeps airways and alveoli open but does not add the inspiratory pressure that clears CO2, so hypoventilation calls for BiPAP)
• Require alveolar recruitment – cardiogenic pulmonary edema and OSA are classic CPAP indications

Intubation criteria and escalation

Intubation and mechanical ventilation are required when non-invasive measures fail or when the clinical situation precludes them. Recognizing the intubation threshold is a core critical care nursing skill – preparation must happen before the patient arrests.

Criteria for escalation to mechanical ventilation:

• Failure of NIV – BTS/ICS 2016 notes that improvement in pH and respiratory rate, usually within 1–2 hours, predicts NIV success; a pH or respiratory rate that worsens, or work of breathing that rises despite NIV with a good mask fit and adequate pressures, means the strategy must change
• GCS ≤ 8 – the patient cannot reliably protect the airway; aspiration risk is unacceptable
• PaO2 < 60 mmHg despite maximum non-invasive supplemental oxygen – refractory hypoxemia not corrected by any mask device or NIV
• Worsening hypercapnic acidosis – BTS/ICS 2016 suggests pH < 7.25 as the level below which intubation should be considered and a persisting pH < 7.15 (or a falling pH despite NIV) as an indication for it. Severe acidosis alone does not rule out a supervised NIV trial in an ICU or HDU with staff ready to intubate. Severe acidosis also increases myocardial irritability (arrhythmia risk) and depresses consciousness
• Apnea or near-apnea – respiratory rate < 8 with decreasing depth; the patient’s respiratory drive is failing
• Cardiorespiratory arrest – intubation is performed as part of resuscitation

Nursing preparation for rapid sequence intubation (RSI):

• Position patient supine with head of bed at 20–30° (allows laryngoscope access while providing some pre-oxygenation benefit)
• Pre-oxygenate with 100% FiO2 for 3–5 minutes via NRB or BVM – extends the safe apnea time
• Draw up medications: succinylcholine or rocuronium (neuromuscular blockade), etomidate or ketamine (induction), vasopressors to anticipate post-intubation hypotension
• Prepare suction, ETT (correct size + one size smaller), laryngoscope, stylet, 10 mL syringe (cuff inflation), tape or commercial securing device
• Attach continuous SpO2 and EtCO2 – waveform capnography confirms ETT placement (sustained waveform = tracheal placement)
• Notify respiratory therapy; have ventilator settings planned before intubation

Post-intubation management is covered in the mechanical ventilation nursing guide.

Nursing interventions

Positioning

Position has a direct effect on respiratory mechanics:

• Head of bed 30–45° for all intubated and mechanically ventilated patients (VAP prevention, reduces aspiration risk, improves diaphragm excursion by reducing abdominal pressure on the chest)
• Semi-recumbent or upright for non-intubated ARF patients – never supine; supine positioning reduces FRC and worsens oxygenation, particularly in obese patients
• Lateral positioning (good lung down) in unilateral lung disease – gravity directs pulmonary blood flow preferentially to the dependent lung, so placing the better-ventilated lung downward matches perfusion to ventilation and improves oxygenation. This applies only when the disease is confined to one side; in diffuse bilateral disease such as ARDS or cardiogenic pulmonary edema there is no “good lung” to make dependent, and the rule does not apply
• Critical exception to good-lung-down: hemoptysis, lung abscess, and empyema. When the diseased lung can spill blood, pus, or infected material, the affected side goes down instead, so gravity keeps the contaminated material in the already-diseased lung rather than draining it into the healthy one. Airway protection outranks V/Q optimization. Massive hemoptysis from any cause (bronchiectasis, lung malignancy, pulmonary artery rupture) follows this exception
• Prone positioning in severe ARDS (P/F < 150 mmHg) – covered in the ARDS nursing reference
• Lateral positioning is an adjunct; the underlying cause still needs treating. Monitor SpO2 before and after any position change and return the patient to a tolerated position if oxygenation falls; the dependent good lung can itself develop atelectasis if the position is held too long

Airway clearance

• Suctioning – perform when secretions are present (audible, visible, SpO2 dropping without other explanation); suction duration ≤ 10–15 seconds; hyperoxygenate before and after; note secretion color, consistency, quantity
• Incentive spirometry – for spontaneously breathing, conscious patients; prevents atelectasis; 10 repetitions per hour while awake
• Chest physiotherapy / percussion – for patients with bronchiectasis, CF, or productive secretions when cough is weak
• Nebulized bronchodilators – albuterol (SABA) for bronchospasm; ipratropium (anticholinergic) added for COPD exacerbation; administer via in-line nebulizer or MDI with spacer on NIV/ventilator circuit

Hemodynamic and metabolic monitoring

• Maintain continuous cardiac monitoring – arrhythmias are common in ARF (hypoxemia and hypercapnia both increase myocardial irritability)
• Monitor potassium closely – albuterol causes hypokalemia; COPD exacerbation patients often have diuretic-related hypokalemia at baseline
• Assess renal function – prerenal AKI is common when hypoxemia causes sympathetic-mediated renal vasoconstriction; monitor urine output and BUN/creatinine
• Fluid balance – restrictive in ARDS; cautious in COPD (excess fluid worsens pulmonary edema); when sepsis is the underlying cause, the 2026 Surviving Sepsis Campaign guideline suggests at least 30 mL/kg of balanced crystalloid within the first 3 hours for hypoperfusion, with reassessment after each bolus for worsening oxygenation or crackles, and early norepinephrine if hypotension persists (see sepsis nursing guide)

Anxiety and communication

Dyspnea is terrifying. Patients in ARF experience profound anxiety that itself increases oxygen demand and worsens tachypnea. Nursing interventions:

• Remain calm and present – reassurance reduces tachypnea and anxiety in hypoxic patients
• Explain every procedure before doing it – even when the patient appears obtunded, explain aloud
• For intubated patients: establish a communication system before sedation is deepened – writing board, eye-blink signals, letter boards
• Avoid excessive sedation – over-sedation suppresses respiratory drive and prolongs mechanical ventilation

Medications commonly used in ARF

NCLEX differentiation: ARF vs related conditions

This table targets the most common NCLEX-tested differentials – conditions that share hypoxemia and dyspnea but require different priority interventions.

Complications to monitor

• Ventilator-associated pneumonia (VAP) – if intubated; SHEA 2022 prevention practices include avoiding intubation where NIV or HFNC will do, minimizing sedation with daily spontaneous awakening and breathing trials, early mobility, HOB 30–45°, daily toothbrushing, plus (as an additional approach) subglottic secretion drainage tubes for patients expected to need more than 48–72 hours of ventilation (SHEA does not recommend chlorhexidine oral care or stress ulcer prophylaxis for VAP prevention); see mechanical ventilation nursing guide
• Barotrauma – pneumothorax, pneumomediastinum, subcutaneous emphysema from elevated airway pressures; monitor for sudden unilateral absent breath sounds, hypotension, tracheal deviation
• Oxygen toxicity – FiO2 > 0.60 sustained beyond 24–48 hours causes oxidative damage; always use lowest effective FiO2
• ICU-acquired weakness and delirium – prolonged mechanical ventilation, sedation, and immobility cause both; early mobilization and minimizing sedation are evidence-based preventive strategies
• Renal failure – prerenal AKI from reduced cardiac output + renal vasoconstriction; monitor urine output and creatinine daily; see AKI nursing reference
• GI stress ulcers – invasive mechanical ventilation is a major risk factor for stress-related GI bleeding; in the REVISE trial (Cook 2024), pantoprazole cut clinically important upper GI bleeding in ventilated patients from 3.5% to 1.0% with no difference in mortality. Give prophylaxis per protocol (a PPI such as pantoprazole, or famotidine; ranitidine was withdrawn from the US market by the FDA in April 2020)
• Hemodynamic instability – positive pressure ventilation reduces venous return; anticipate hypotension after intubation (post-intubation hypotension); vasopressors may be required; norepinephrine is first-line in septic shock with ARF (see shock nursing reference)

Patient and family education

When the patient has stabilized – either extubated or weaned to low-level oxygen support – education focuses on the underlying cause and prevention of recurrence.

Underlying cause management:

• COPD: medication adherence (inhaled corticosteroid/LABA maintenance), action plan for exacerbations, when to call 911 (increasing dyspnea, unable to complete sentences, SpO2 falling), home BiPAP if prescribed
• Asthma: trigger avoidance, controller vs. rescue inhaler distinction, peak flow monitoring, action plan
• Opioid-induced ARF: naloxone kit education for patient and family; safe opioid storage; risk of relapse after tolerance reset
• Heart failure: daily weights, fluid restriction, diuretic adherence, sodium restriction; see heart failure nursing guide

For patients discharged on home oxygen:

• Flow rate and hours per day are prescribed – do not adjust without provider guidance
• Fire safety: no smoking, no open flames; oxygen supports combustion
• Nasal dryness and epistaxis – nasal saline or a water-based lubricant (never petroleum jelly near oxygen); a humidifier bottle may help higher flows, though BTS does not require humidification for low-flow oxygen
• When to seek emergency care – defined SpO2 threshold and symptom list; never delay calling 911 if acutely short of breath

Smoking cessation: Smoking is the primary modifiable risk factor for COPD, lung cancer, and cardiovascular disease – all leading causes of ARF. Every hospitalization is an opportunity to initiate cessation counseling and pharmacotherapy (nicotine replacement, varenicline, bupropion). The hospitalized patient’s motivation is often highest during acute illness.

NCLEX tips

1. PaO2 < 60 mmHg = ARF. This is the threshold. Normal PaO2 is 80–100 mmHg. PaO2 60–79 mmHg is hypoxemia but does not meet the ARF definition. Commit this number.

2. Type I = oxygenation failure (V/Q mismatch / shunt). Type II = ventilation failure (CO2 cannot be cleared). The NCLEX tests whether you know which type is present and which intervention follows.

3. PaCO2 > 45 mmHg = Type II ARF. Rising CO2 means the patient cannot ventilate adequately. Falling pH with rising CO2 = decompensated respiratory acidosis.

4. Shunt does NOT respond to 100% supplemental oxygen. This distinguishes ARDS from simple V/Q mismatch. A PaO2 that fails to rise appropriately with high-flow O2 suggests true shunt (ARDS, massive atelectasis).

5. BiPAP = first-line for COPD exacerbation with hypercapnia. This is one of the highest-yield NCLEX answers in respiratory failure. If the question says COPD + rising CO2 + SpO2 88% on 2L NC – the next intervention is BiPAP, not intubation.

6. SpO2 target in COPD = 88–92%. Higher targets in patients at risk of hypercapnia worsen CO2 retention, mainly by worsening V/Q matching, with reduced hypoxic drive and the Haldane effect contributing. 94–98% is the standard target for most other patients. Never withhold oxygen from a hypoxemic COPD patient, and never stop it abruptly (rebound hypoxemia); titrate it.

7. Normal pH in a COPD patient does not mean the patient is stable. A pH of 7.37 with PaCO2 of 68 and HCO3 of 38 represents fully compensated chronic respiratory acidosis – this patient lives in this state. An acute rise to PaCO2 75 may not change the pH significantly but represents decompensation.

8. Asterixis = CO2 narcosis. This flapping hand tremor indicates hypercapnic encephalopathy. Assess by having the patient extend arms – inability to maintain posture with flapping = positive asterixis.

9. BiPAP is contraindicated with vomiting. A patient who is actively vomiting cannot safely tolerate positive pressure with a tight-fitting face mask. Remove the mask immediately; suction first.

10. pH < 7.25 with rising PaCO2 = intubation discussion becomes urgent. BTS/ICS 2016 suggests considering intubation below pH 7.25 and treats a persisting pH < 7.15 or a falling pH despite NIV as an indication for it. Acidosis this severe causes myocardial depression and arrhythmias. Any NIV trial at this level belongs in an ICU or HDU with staff ready to intubate.

11. Naloxone can wear off before the opioid does. A patient who responds to naloxone can re-narcotize. Keep them under continued observation, repeat doses as needed, and consider a naloxone infusion for long-acting opioid overdose.

12. ARDS is non-cardiogenic pulmonary edema. The NCLEX will present ARDS and heart failure with bilateral infiltrates and hypoxemia. Older textbooks separate them with a PAWP ≤ 18 mmHg, a cutoff from the 1994 consensus definition. The Berlin (2012) and 2024 global definitions dropped it: ARDS is diagnosed when the edema is not primarily explained by heart failure or fluid overload, judged clinically and, if no risk factor for ARDS is present, by objective assessment such as echocardiography. An S3 or raised JVD points toward a cardiac cause.

13. Rising respiratory rate with falling SpO2 = early ARF. Tachypnea is one of the earliest signs; wait for SpO2 to fall and you have lost time. Act on tachypnea and increased work of breathing even while SpO2 still looks acceptable.

14. Mental status change in a hypoxic patient is a clinical emergency. New confusion, agitation, or drowsiness in a patient with respiratory disease requires immediate ABG and reassessment of oxygen therapy. Do not attribute confusion to anxiety or sedation without ruling out hypoxemia and hypercapnia.

15. FiO2 > 0.60 for > 24–48 hours causes oxygen toxicity. Titrate down as quickly as oxygenation allows. Always use lowest effective FiO2 – especially after intubation.

NCLEX-style practice questions

Question 1

A patient with known COPD presents to the emergency department with worsening dyspnea. SpO2 is 84% on room air. ABG shows: pH 7.29, PaCO2 62 mmHg, PaO2 48 mmHg, HCO3 28 mEq/L. What is the nurse’s priority intervention?

A) Apply a non-rebreather mask at 15 L/min to correct hypoxemia rapidly
B) Prepare the patient for immediate intubation
C) Apply BiPAP and titrate supplemental oxygen to achieve SpO2 88–92%
D) Administer IV methylprednisolone and repeat the ABG in 4 hours

Answer: C – BiPAP with controlled oxygen titration

Rationale: This patient has Type II ARF (PaCO2 > 45, pH < 7.35, hypoxemia) in the setting of COPD. BiPAP is the first-line intervention for COPD exacerbation with hypercapnic respiratory failure. It reduces work of breathing and improves CO2 clearance; in the 2017 Cochrane review it cut the need for intubation by 65% and mortality by 46%. Controlled oxygen targeting SpO2 88–92% limits oxygen-induced hypercapnia, which comes mainly from worsened V/Q matching, with reduced hypoxic drive contributing. Option A is incorrect – a non-rebreather at 15 L/min would push SpO2 above 92% in most cases, risking further CO2 retention. Option B is premature – NIV should be trialed first unless contraindicated. Option D (steroids + wait) is an appropriate adjunct but is not the priority intervention for a patient with SpO2 84%.

Question 2

A nurse is caring for a patient who received IV hydromorphone 15 minutes ago. The patient now has a respiratory rate of 6 breaths/minute and is unresponsive. SpO2 is 82%. What is the nurse’s first action?

A) Draw an ABG to confirm the diagnosis
B) Administer naloxone and prepare for airway management
C) Increase supplemental oxygen to non-rebreather at 15 L/min
D) Call the rapid response team, then prepare BiPAP

Answer: B – Administer naloxone and prepare for airway management

Rationale: This presentation is consistent with opioid-induced respiratory depression (Type II ARF) – recent opioid administration, bradypnea (RR 6), loss of consciousness. Naloxone (0.4 mg IV/IM/SC) is the specific reversal agent and should be given immediately while simultaneously preparing for possible airway management (BVM ventilation, intubation). Supplemental oxygen alone will not reverse the central respiratory depression. BiPAP is contraindicated in an unresponsive patient who cannot protect the airway. Obtaining an ABG is appropriate but is not the first action – reversal and airway management take precedence.

Question 3

A nurse is caring for a mechanically ventilated patient with ARDS. The current ABG shows: pH 7.28, PaCO2 52 mmHg, PaO2 58 mmHg, HCO3 23 mEq/L. Ventilator settings: Vt 420 mL (6 mL/kg IBW), FiO2 0.65, PEEP 10 cmH2O. Which finding is most consistent with appropriate lung-protective management?

A) The tidal volume is too low and should be increased to normalize PaCO2
B) The elevated PaCO2 indicates permissive hypercapnia consistent with lung-protective ventilation
C) FiO2 should be increased to 1.0 to correct hypoxemia before addressing the acidosis
D) The patient should be extubated because the respiratory acidosis indicates ventilator dyssynchrony

Answer: B – Elevated PaCO2 reflects permissive hypercapnia, consistent with lung-protective ventilation

Rationale: Lung-protective ventilation targets 6 mL/kg IBW and plateau pressure < 30 cmH2O, even at the cost of mild hypercapnia. Permissive hypercapnia means accepting a raised PaCO2 instead of increasing tidal volume to normalize CO2, which would worsen volutrauma. The ARDS Network protocol sets a pH goal of 7.30–7.45: at pH 7.28 the next step is to increase the respiratory rate (up to 35/min), leaving the 6 mL/kg tidal volume unchanged. The PaO2 of 58 mmHg is within the protocol’s oxygenation goal of 55–80 mmHg. Option A is incorrect – increasing Vt worsens lung injury. Option C is incorrect – FiO2 should be titrated to the lowest effective level; maximizing FiO2 risks oxygen toxicity and does not address the CO2 problem. Option D is incorrect – the patient is in active ARF; extubation is not indicated.

Related references

Conditions that frequently present with acute respiratory failure or are caused by it:

• ABG interpretation guide – essential for classifying ARF type and monitoring response to treatment; includes the 5-step ROME method
• ARDS nursing reference – the most severe form of Type I ARF; Berlin Definition, P/F ratio, prone positioning, lung-protective ventilation
• Mechanical ventilation nursing guide – comprehensive reference for intubated ARF patients; modes, settings, alarms, weaning, VAP bundle
• COPD nursing reference – the leading cause of Type II ARF; exacerbation management, BiPAP indications, hypoxic drive, spirometry
• Asthma nursing guide – status asthmaticus is a cause of Type II ARF; stepwise treatment, heliox, magnesium
• Pneumonia nursing guide – the most common direct cause of Type I ARF; community vs hospital-acquired, antibiotic selection
• Pulmonary embolism nursing reference – causes Type I ARF via dead-space physiology; Wells score, anticoagulation, massive PE management
• Heart failure nursing guide – cardiogenic pulmonary edema is a primary cause of Type I ARF; Frank-Starling, diuresis, afterload reduction
• Sepsis nursing reference – sepsis is the leading indirect cause of ARF and ARDS; Sepsis-3 criteria, fluid resuscitation, vasopressors
• Shock nursing reference – distributive, cardiogenic, obstructive shock all produce ARF; hemodynamic targets, vasopressor selection

This article is for educational purposes. Always apply clinical judgment and follow your institution’s evidence-based protocols when caring for patients with acute respiratory failure.

References

1. The ARDS Definition Task Force (Ranieri VM, Rubenfeld GD, Thompson BT, et al). Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–2533. doi:10.1001/jama.2012.5669
2. Matthay MA, Arabi Y, Arroliga AC, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2024;209(1):37–47. doi:10.1164/rccm.202303-0558WS
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD: 2026 Report. 2026. Available at: https://goldcopd.org
4. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine. 1995;333(13):817–822. doi:10.1056/NEJM199509283331301
5. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. New England Journal of Medicine. 2015;372(23):2185–2196. doi:10.1056/NEJMoa1503326
6. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. New England Journal of Medicine. 2000;342(18):1301–1308. doi:10.1056/NEJM200005043421801
7. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine. 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST (supersedes the 2007 IDSA/ATS guideline)
8. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. European Respiratory Journal. 2017;50(2):1602426. doi:10.1183/13993003.02426-2016
9. Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Medicine. 2026;52(5):863–936. doi:10.1007/s00134-026-08361-1 (supersedes the 2016 and 2021 editions)
10. Rochwerg B, Einav S, Chaudhuri D, et al. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. Intensive Care Medicine. 2020;46(12):2226–2237. doi:10.1007/s00134-020-06312-y
11. Gillespie DJ, Rehder K. Body position and ventilation-perfusion relationships in unilateral pulmonary disease. Chest. 1987;91(1):75–79. doi:10.1378/chest.91.1.75
12. Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. New England Journal of Medicine. 2013;368(23):2159–2168. doi:10.1056/NEJMoa1214103
13. Amato MBP, Barbas CSV, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. New England Journal of Medicine. 1998;338(6):347–354. doi:10.1056/NEJM199802053380602
14. Hess DR. Patient positioning and ventilator-associated pneumonia. Respiratory Care. 2005;50(7):892–899. PMID:15972110
15. Davidson K, Shojaee S. Managing massive hemoptysis. Chest. 2020;157(1):77–88. doi:10.1016/j.chest.2019.07.012
16. O’Driscoll BR, Howard LS, Earis J, Mak V; British Thoracic Society Emergency Oxygen Guideline Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1):ii1–ii90. doi:10.1136/thoraxjnl-2016-209729 (section 6.3.1: mechanisms of oxygen-induced hypercapnia)
17. Aubier M, Murciano D, Milic-Emili J, et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. American Review of Respiratory Disease. 1980;122(5):747–754. doi:10.1164/arrd.1980.122.5.747 PMID:6778278
18. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462. doi:10.1136/bmj.c5462
19. Davidson AC, Banham S, Elliott M, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax. 2016;71(Suppl 2):ii1–ii35. doi:10.1136/thoraxjnl-2015-208209
20. Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2017;7:CD004104. doi:10.1002/14651858.CD004104.pub4
21. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–2231. doi:10.1001/jama.2013.5023
22. NIH NHLBI ARDS Clinical Network. Mechanical ventilation protocol summary (pH goal 7.30–7.45; oxygenation goal PaO2 55–80 mmHg or SpO2 88–95%; plateau pressure ≤ 30 cmH2O). ardsnet.org, 2008.
23. Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update. Infection Control & Hospital Epidemiology. 2022;43(6):687–713. doi:10.1017/ice.2022.88
24. Cook D, Deane A, Lauzier F, et al. Stress ulcer prophylaxis during invasive mechanical ventilation. New England Journal of Medicine. 2024;391(1):9–20. doi:10.1056/NEJMoa2404245
25. US Food and Drug Administration. FDA requests removal of all ranitidine products (Zantac) from the market. News release, April 1, 2020.
26. Naloxone hydrochloride injection, USP – prescribing information (Hospira). DailyMed, US National Library of Medicine (setid 8535cc84-ad4a-4d67-8480-fb5a2e3406f8); NARCAN (naloxone hydrochloride) nasal spray 4 mg – prescribing information. DailyMed. Accessed October 10, 2026.